fevipiprant
Small moleculeexperimental
Fevipiprant (INN; code name QAW039) is a drug of the piprant class that was being developed by Novartis. It is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). — Wikipedia
Clinical trial activity
20 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
17
Phase 3
6
Phase 4
1
Earliest trial started Nov 1, 2010 (NCT01253603)
Timeline
Indications
Approved for
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
PTGDR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F- Mol. weight
- 426.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFevipiprant ↗
- ChEMBLCHEMBL3137332 ↗
Also known as
- 1-(4-methanesulfonylbenzyl)-2-methyl-1h-pyrrolo(2,3-b)pyridin-3-yl)acetic acid
- fevipiprant
- fevipiprant
- fevipiprant
- fevipiprant
- fevipiprant
- nvp-qaw039
- nvp-qaw039
- nvp-qaw039
- qaw039
- qaw039
- qaw039
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03989635 | Phase 2 | Aug 16, 2019 | Novartis |
| NCT03810183 | Phase 2 | May 24, 2019 | Novartis |
| NCT03956862 | Phase 2 | Apr 30, 2019 | Gossamer Bio Inc. |
| NCT03681093 | Phase 3 | Jan 21, 2019 | Novartis |
| NCT03629249 | Phase 4 | Dec 7, 2018 | Novartis |
| NCT03650400 | Phase 2 | Nov 8, 2018 | Novartis |
| NCT03683576 | Phase 2 | Sep 26, 2018 | Gossamer Bio Inc. |
| NCT03215758 | Phase 3 | Nov 1, 2017 | Novartis |
| NCT03226392 | Phase 3 | Oct 31, 2017 | Novartis |
| NCT03087942 | Phase 1 | Jun 7, 2017 | Novartis |
| NCT03048448 | Phase 1 | Jun 5, 2017 | Novartis |
| NCT03052517 | Phase 3 | Mar 21, 2017 | Novartis |
| NCT02555683 | Phase 3 | Dec 11, 2015 | Novartis |
| NCT02563067 | Phase 3 | Dec 3, 2015 | Novartis |
| NCT01785602 | Phase 2 | Jun 1, 2013 | Novartis |
| NCT01836471 | Phase 2 | May 1, 2013 | Novartis |
| NCT01804400 | Phase 2 | Oct 1, 2012 | Novartis |
| NCT01545726 | Phase 2 | Feb 1, 2012 | Novartis |
| NCT01437735 | Phase 2 | Aug 1, 2011 | Novartis |
| NCT01253603 | Phase 2 | Nov 1, 2010 | Novartis |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 18 | 18 | 4 | 2010 |
| Gossamer Bio Inc. | For profit | 2 | 2 | 1 | 2018 |
2 organizations
Page 1 / 1